

# Accepted Manuscript

Fibroblast Growth Factor 21 Limits Lipotoxicity by Promoting Hepatic Fatty Acid Activation in Mice on Methionine and Choline-deficient Diets

Ffolliott M. Fisher, Patricia C. Chui, Imad A. Nasser, Yury Popov, Jeremy C. Cunniff, Thomas Lundasen, Alexei Kharitonov, Detlef Schuppan, Jeffrey S. Flier, Eleftheria Maratos-Flier

PII: S0016-5085(14)00969-X  
DOI: [10.1053/j.gastro.2014.07.044](https://doi.org/10.1053/j.gastro.2014.07.044)  
Reference: YGAST 59271

To appear in: *Gastroenterology*  
Accepted Date: 21 July 2014

Please cite this article as: Fisher FM, Chui PC, Nasser IA, Popov Y, Cunniff JC, Lundasen T, Kharitonov A, Schuppan D, Flier JS, Maratos-Flier E, Fibroblast Growth Factor 21 Limits Lipotoxicity by Promoting Hepatic Fatty Acid Activation in Mice on Methionine and Choline-deficient Diets, *Gastroenterology* (2014), doi: 10.1053/j.gastro.2014.07.044.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

All studies published in *Gastroenterology* are embargoed until 3PM ET of the day they are published as corrected proofs on-line. Studies cannot be publicized as accepted manuscripts or uncorrected proofs.



**Manuscript Number:** GASTRO 13-01577

## **Fibroblast Growth Factor 21 Limits Lipotoxicity by Promoting Hepatic Fatty Acid Activation in Mice on Methionine and Choline-deficient Diets**

**Short Title:** FGF21 and steatohepatitis.

ffolliott M. Fisher<sup>1\*¥</sup>, Patricia C. Chui<sup>1\*</sup>, Imad A. Nasser<sup>2</sup>, Yury Popov<sup>3</sup>, Jeremy C. Cunniff<sup>1</sup>, Thomas Lundasen<sup>1</sup>, Alexei Kharitononkov<sup>4</sup>, Detlef Schuppan<sup>3,5</sup>, Jeffrey S. Flier<sup>1</sup>, and Eleftheria Maratos-Flier<sup>1</sup>

<sup>1</sup> Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215

<sup>2</sup> Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215

<sup>3</sup> Department of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215

<sup>4</sup> Eli Lilly and Company, Diabetes Research, Indianapolis, IN 46285

<sup>5</sup> Institute of Molecular and Translational Medicine and Dept. of Medicine I, University of Mainz Medical School, Germany

**Grant Support:** R37 DK28082 (J.S.F. and EMF) and Fibroblast growth factor 21 limits lipotoxicity in NAFLD by driving hepatic fatty acid activation in mice. T32 DK007760-12 (P.C.C.)

**\* Authors contributed equally**

¥ Corresponding Author:

ffolliott Martin Fisher, Instructor in Medicine

Department of Medicine, Harvard Medical School

Beth Israel Deaconess Medical Center

Center for Life Sciences, 7<sup>th</sup> floor

3 Blackfan Street

Boston, MA 02215

Mfisher3@bidmc.harvard.edu

**Disclosures:** A.K. works for Eli Lilly and Co. E.M.-F. has consulted for Novo/Nordisk and Novartis regarding FGF21. The remaining authors have no conflict of interest to report.

**Author Contributions:** F.M.F. Wrote manuscript designed and planned study, researched data. P.C.C. Wrote manuscript designed and planned study, researched data. I.N. researched data. Y.P. researched data. J.C. researched

Download English Version:

<https://daneshyari.com/en/article/6094742>

Download Persian Version:

<https://daneshyari.com/article/6094742>

[Daneshyari.com](https://daneshyari.com)